Vaccine compositions and methods containing an immunogen derived from equine arteritis virus
OwnerMatthias Gieseinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to vaccine compositions comprising a nucleic acid encoded by an equine arterivirus virus (EAV) open reading frame (ORF) 2 nucleic acid, and a nucleic vector comprising said EAV ORF 2. The invention further relates to the methods and kits encompassing the use of EAV ORF 2 containing vaccine compositions and nucleic acid vectors for the prevention and/or treatment of EAV infections.
Claims15
A nucleic acid vaccine composition that is protective against the Arteriviridae family and induces a cellular immune response, said vaccine encodes only one equine arteritis virus (EAV) protein consisting of open reading frame (ORF) 2 or 2b, wherein the coding sequence for ORF 2 or 2b is SEQ ID NO:1 or SEQ ID NO:2, wherein said vaccine composition is administered as a single base immunization without a booster, or as a base immunization followed by a first boost after 8-12 weeks, or as a base immunization followed by a first boost after 8-12 weeks and a second boost after 12 months.
Dependencies are inferred from the claim text.